IL-4/IL-13 Dual Cytokine Signaling in Severe Asthma: Mechanistic Insights by Prof. Kenneth Chapman
Recognizing the key cytokines driving type 2 inflammation and understanding their profound impact on patients’ asthma burden is crucial.1-3
This website is intended exclusively for healthcare professionals residing and/or working in the KSA.

Recognizing the key cytokines driving type 2 inflammation and understanding their profound impact on patients’ asthma burden is crucial.1-3

What’s New in the GOLD 2026 Report

Progression Independent of Relapse Activity (PIRA) represents the gradual, sustained worsening of disability that occurs even without relapses. In this video, Dr. Barry Singer explains how PIRA is defined, why it affects many patients across the MS spectrum, and how clinicians can better detect subtle changes that reflect true long-term progression.

A simplified walkthrough of how 6‑month Confirmed Disability Progression (CDP) is measured in MS clinical trials. Dr. Barry Singer explains how EDSS changes are assessed, why sustained progression matters, and how this endpoint helps distinguish real, lasting disability worsening from temporary fluctuations.

Kaplan–Meier curves play a key role in visualizing how clinical events—such as confirmed disability progression—evolve over time in MS studies. In this video, Dr. Barry Singer provides a clear, simplified walkthrough of how these curves are constructed, how patient data contributes to each step, and what curve separation really tells us about treatment impact. This resource offers an accessible foundation for anyone looking to better understand KM interpretation in MS research.
Skin involvement represents the most frequent and often earliest manifestation of both acute and chronic GvHD, with significant diagnostic and therapeutic implications. In this episode, Dr. Marawan and Dr. Yousef provide a comprehensive, multidisciplinary review of clinical presentation, differential diagnosis, histopathologic correlation, NIH grading criteria, and the functional and quality-of-life impact of cutaneous GvHD. The discussion also addresses challenges in distinguishing chronic skin GvHD from autoimmune mimickers and highlights the importance of early recognition and coordinated care to optimize patient outcomes.
Podcast describing Umrah as mass gathering as well as the data related to the IMD modeling

Eosinophilic inflammation has multiple drivers1,2